Plain-English translation of NCT07582835 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After you have a heart stent placed, doctors typically give you blood-thinning medications to prevent clots. This trial is testing whether lower doses of or work just as well as standard doses of at keeping your blood thin enough to prevent clots, but without causing too much bleeding. The study will measure how your blood clots respond to each medication to find the safest and most effective dose for you.
Right now, doctors don't know the best dose of these medications to use after a stent—some people's blood clots too much (risking a heart attack), while others' blood thins too much (risking dangerous bleeding). This trial aims to find the 'sweet spot' dose that protects your heart without causing bleeding problems.
You likely qualify if…
You likely don't qualify if…
The study has two parts. First, you will have blood tests performed at different doses of the medications to see how your blood responds—this helps doctors find your ideal dose. Then, you will be randomly assigned to take one of three blood-thinning medications (either standard-dose or an optimized dose of or ) for long-term treatment. Throughout the study, you'll have regular blood tests and clinic visits to monitor how the medication is working and to check for any side effects.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Switzerland